MET and renal carcinoma: Balan et al found that both c-MET and PD-L1 could be significantly up-regulated and co-localized in renal cancer tissues and that using c-MET inhibitors could down-regulate the expression of PD-L1.[11] This shows that c-MET is vital in tumor immune escape through the Ras-PI3K pathway and PD-L1 expression in renal cancer cells.